Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
Clinical-stage biotech developing allogeneic CAR-T therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New cell therapy takes on advanced kidney cancer
Disease control OngoingThis early-stage study tests a new treatment called ALLO-316 for people with advanced or spreading clear cell kidney cancer who have already tried standard therapies like checkpoint inhibitors and VEGF inhibitors. The treatment uses specially designed immune cells from a donor to…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Off-the-Shelf CAR t therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …
Phase 1/2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC